ZLAB Dec 2024 20.000 put
| Previous close | 4.6000 |
| Open | 4.6000 |
| Bid | 3.6000 |
| Ask | 4.5000 |
| Strike | 20.00 |
| Expiry date | 2024-12-20 |
| Day's range | 4.6000 - 4.6000 |
| Contract range | N/A |
| Volume | |
| Open interest | 1.62k |
Simply Wall St.Increases to CEO Compensation Might Be Put On Hold For Now at Zai Lab Limited (NASDAQ:ZLAB)
Key Insights Zai Lab's Annual General Meeting to take place on 18th of June CEO Samantha Du's total compensation...
Business WireZai Lab Announces Dr. Harald Reinhart to Retire as Head of Global Development for Neuroscience, Autoimmune and Infectious Diseases; Dr. Rafael Amado to be Appointed President, Head of Global R&D
SHANGHAI & CAMBRIDGE, Mass., June 11, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) announced today that following a distinguished career, Harald Reinhart, M.D., President, Head of Global Development, Neuroscience, Autoimmune and Infectious Diseases (NSAiID) of Zai Lab, will retire at the end of June, after which he will serve as a senior advisor for the Company. Rafael Amado, M.D., President, Head of Global Oncology Research and Development of Zai Lab, will expand his role and assume respons
Business WireZai Lab Initiates Global Phase 2 Clinical Trial Evaluating ZL-1102 As a Topical Treatment for Chronic Plaque Psoriasis
SHANGHAI & CAMBRIDGE, Mass., May 22, 2024--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the first patient has been dosed in a global Phase 2 clinical trial (NCT06380907) evaluating the efficacy and safety of the company’s internally developed anti-IL-17 investigational therapy, ZL-1102, for the treatment of chronic plaque psoriasis (CPP). ZL-1102 is a novel human VH antibody fragment (Humabody®) targeting the IL-17 cytokine. Emphasizing its unique approach, ZL-1102 is being de
